Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
(2022) Leukemia and Lymphoma — Vol. 63, n° 3, p. 743-746 (2022)
Files
2021_Saad_Albichr_Leuk_Lymphoma.pdf
Open Access - Adobe PDF
- 463.13 KB
Details
- Authors
- Abstract
- SARS-CoV-2 vaccines offered great hope in controlling the worldwide COVID-19 pandemic. At present, SARS-CoV-2 vaccines have shown excellent efficacy to prevent COVID-19 but immunocompromised patients were left-off most vaccine clinical trials albeit their extreme vulnerability. Indeed, immunosuppression is associated with a higher risk of developing severe COVID-19 with mortality rates over 30% reported in patients with hematologic malignancies (HM). [...]
- Affiliations
Citations
Saad Albichr, I., De Greef, J., Van Den Neste, E., Poire, X., Havelange, V., Vekemans, M.-C., Bailly, S., Yombi, J. C., Mzougui, S., Scohy, A., & Kabamba-Mukadi, B. (2022). Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders? Leukemia and Lymphoma, 63(3), 743-746. https://doi.org/10.1080/10428194.2021.1998485 (Original work published 2022)